Thurston Springer Miller Herd & Titak Inc. Trims Holdings in Zoetis Inc. $ZTS

Thurston Springer Miller Herd & Titak Inc. trimmed its holdings in Zoetis Inc. (NYSE:ZTS) by 94.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 826 shares of the company’s stock after selling 13,153 shares during the quarter. Thurston Springer Miller Herd & Titak Inc.’s holdings in Zoetis were worth $121,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of the business. Brighton Jones LLC lifted its holdings in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares during the last quarter. Steward Partners Investment Advisory LLC increased its position in Zoetis by 2.6% during the 1st quarter. Steward Partners Investment Advisory LLC now owns 49,387 shares of the company’s stock valued at $8,132,000 after buying an additional 1,236 shares in the last quarter. Brooklyn Investment Group raised its stake in Zoetis by 8.8% during the first quarter. Brooklyn Investment Group now owns 3,978 shares of the company’s stock valued at $655,000 after buying an additional 323 shares during the last quarter. Northern Trust Corp boosted its holdings in Zoetis by 1.2% in the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after acquiring an additional 78,508 shares in the last quarter. Finally, Aptus Capital Advisors LLC grew its stake in shares of Zoetis by 96.6% in the first quarter. Aptus Capital Advisors LLC now owns 13,062 shares of the company’s stock worth $2,151,000 after acquiring an additional 6,419 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of ZTS stock opened at $123.36 on Wednesday. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The company has a 50 day moving average price of $130.07 and a 200-day moving average price of $145.30. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.40. The firm has a market capitalization of $54.36 billion, a PE ratio of 20.77, a P/E/G ratio of 2.51 and a beta of 0.97.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter in the prior year, the firm earned $1.58 earnings per share. The firm’s revenue for the quarter was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Tuesday, January 20th. This is an increase from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. Zoetis’s dividend payout ratio is presently 33.67%.

Analysts Set New Price Targets

Several research firms have recently issued reports on ZTS. UBS Group lowered their price target on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research report on Wednesday, November 5th. Bank of America lowered shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price objective for the company. in a research note on Monday. BTIG Research reiterated a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research note on Wednesday, December 3rd. Barclays began coverage on shares of Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target on the stock. Finally, HSBC set a $140.00 price objective on shares of Zoetis in a report on Wednesday, December 10th. Six investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $161.55.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.